Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial

RCT (n-226) found after 50.4 months, medical management (MM) alone remained superior to MM plus interventional therapy for prevention of death/symptomatic stroke (events in 15 of 110; 3.39/100 patient-years vs. 41 of 116; 12.32/100, respectively, HR 0.31, 95% CI 0.17-0.56).


The Lancet Neurology